Butylscopolamine

Author: Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 10.10.2026

Dieser Artikel auf Deutsch

Synonym(s)

Butylscopolamines; Hyoscine butyl bromides; N-Butylscopolaminium bromide

Definition
This section has been translated automatically.

Butylscopolamine bromide is a semisynthetic active ingredient belonging to the class of muscarinic receptor antagonists (parasympatholytics) that contains a quaternary ammonium group. The substance, with the molecular formulaC21H30BrNO4, has a molar mass of 440.37 g⋅mol-1. Butylscopolamine bromide is an ammonium derivative of scopolamine and, unlike scopolamine, has high polarity due to its quaternary ammonium group, which ensures that it has no central nervous system effects (when the blood-brain barrier is intact) (Tytgat GN 2008) or, at most, only peripheral effects (Graefe KH 2016); it is therefore extremely hydrophilic and nearly lipophobic.

Pharmacodynamics (Effect)
This section has been translated automatically.

Butylscopolamine is a nonselective antagonist at all five cholinergic receptor subtypes (M1 throughM5). As a result, the substance has an antispasmodic effect on smooth muscle. In pharmacotherapy, it is used in the form of its bromide salt, N-butylscopolamine bromide, both orally and parenterally as an antispasmodic. In addition, butylscopolamine bromide inhibits peristalsis in the stomach and intestines.

You might also be interested in

Field of application/use
This section has been translated automatically.

Butylscopolamine bromide can be administered orally or rectally for mild cramps, despite its very low absorption rate (1–6%). For severe cramp-like pain, the active ingredient can be administered intramuscularly, subcutaneously, or intravenously.

Orally administered butylscopolamine bromide is used to treat intestinal cramps or cramp-related abdominal pain. Its efficacy has been demonstrated both in Phase III studies involving patients with irritable bowel syndrome over a four-week period and in cases of recurrent cramp-like abdominal pain over a three-week period (Tytgat GN 2008).

Butylscopolamine bromide is frequently administered parenterally in combination with metamizole for severe biliary or ureteric colic, although its efficacy in ureteric colic is questioned (Papadopoulos G et al).

Dosage and method of use
This section has been translated automatically.

Single dose for oral administration: 10 to 20 mg butylscopolaminium bromide; maximum daily dose: 60 mg butylscopolaminium bromide.

Single dose for parenteral administration: Adults with acute spastic pain receive 1 - 2 ampoules of Buscopan (single dose: 20 - 40 mg butylscopolaminium bromide; maximum daily dose: up to 100 mg butylscopolaminium bromide). The injection can be administered i. m., s. c. or slowly i. v.

Overdose symptoms are rare and are treated with the cholinesterase inhibitor physostigmine.

Undesirable effects
This section has been translated automatically.

Due to the antagonistic effect of butylscopolamine bromide on muscarinic acetylcholine receptors and the resulting parasympatholytic effect, the following side effects occur; these are generally mild, dose-dependent, and reversible:

Constipation/bowel atony, dry mouth (inhibition of salivary secretion), accommodation disorder/mydriasis, tachycardia, urinary dysfunction/urinary retention, hypohidrosis, nausea, drop in blood pressure, dizziness. Isolated cases of sudden death following intramuscular administration have been reported (Ikegaya H et al. 2006). 

Contraindication
This section has been translated automatically.

Untreated angle-closure glaucoma, cardiac arrhythmia/tachycardia, heart failure, pregnancy/breastfeeding, prostatic hyperplasia, thyrotoxicosis, hereditary fructose intolerance, megacolon, paralytic or obstructive ileus, myasthenia gravis, (mechanical) strictures in the gastrointestinal tract

Preparations
This section has been translated automatically.

Buscopan®

Literature
This section has been translated automatically.

  1. DGU: S2k Guideline for the Diagnosis, Therapy and Metaphylaxis of Urolithiasis (AWMF Registry Number 043 - 025), updated 2018
  2. Graefe KH et al muscarinic receptor antagonists. In: Graefe KH et al (Eds) Pharmacology and Toxicology. Georg Thieme Publisher Stuttgart S.114-115
  3. Ikegaya H et al (2006) A case of sudden death after intramuscular injection of butylscopolamine bromides. Leg Med (Tokyo)8:194-197.
  4. Knoll T et al (2016) S2k guidelines on diagnostics, therapy and metaphylaxis of urolithiasis (AWMF 043/025): Abstract [S2k guidelines on diagnostics, therapy and metaphylaxis of urolithiasis (AWMF 043/025): Compendium]. Urologist A 55:904-922.
  5. Papadopoulos G et al (2014) Hyoscine N-butylbromide (Buscopan®) in the treatment of acute ureteral colic: what is the evidence? Urol Int 92:253-257.
  6. Tytgat GN (2008) Hyoscine butylbromide - a review on its parenteral use in acute abdominal spasm and as an aid in abdominal diagnostic and therapeutic procedures. Curr Med Res Opin 24):3159-3173.

Incoming links (2)

Parasympatholytics; Tiotropium bromide;

Outgoing links (1)

Parasympatholytics;

Authors

Last updated on: 10.10.2026